# Endocrinology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Alan Turing (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML007-SYN
- Date: 2026-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rupert Hallam, MD
- Calendar frame: modern shifted

- To: Celia Montrose-Adeyemi, MD, Endocrinology
- Urgency: Soon, within two weeks

## Referral question

Bilateral tender gynecomastia, suppressed testosterone and gonadotropins, and low libido in a 40-year-old man three weeks after the last of a year of high-dose estrogen injections given without his free consent. Please confirm the cause, advise what further tests are needed, and advise on recovery, testosterone therapy, bone health, and surgery. **S**

## Questions for the consultant

1. Does the exogenous estrogen fully explain the gynecomastia and the hormone results, and what further tests are needed to exclude another cause?
2. How quickly should the hypothalamic-pituitary-gonadal axis recover, and how should we monitor it?
3. Is testosterone therapy, tamoxifen, or an aromatase inhibitor indicated now?
4. Is the raised prolactin significant?
5. How should we protect and assess his bone health?
6. When should surgery be considered if the gynecomastia persists?

## Pertinent history

For about a year, until three weeks ago, he received high-dose estrogen injections abroad as a condition imposed after a criminal conviction for a consensual relationship with another adult man; he did not freely consent and wants no further doses. Over that year his breasts enlarged and became tender, his libido and erections disappeared, and his running fell off. Examination today shows firm, tender, symmetric glandular tissue about 4 cm across behind each nipple, with no discrete mass, skin change, discharge, or axillary nodes, and soft, slightly small testes without masses. Total testosterone 112 ng/dL, estradiol 148 pg/mL, LH 0.3 and FSH 0.4 mIU/mL, prolactin 21.6 ng/mL, SHBG 88 nmol/L, hCG beta 1 mIU/mL, AFP 2.6 ng/mL, liver tests, creatinine, and TSH normal, hemoglobin 13.0 g/dL, and 25-hydroxyvitamin D 22 ng/mL. He takes no other medicine, anabolic steroid, or supplement, and drinks two or three drinks a week. He is also being treated here for a moderate depressive episode, with psychotherapy; PHQ-9 15 with no suicidal ideation. Cholecalciferol 1,000 units daily was started today. He is a long-distance runner and a gay man; he asks that every test and treatment be explained to him first. **S**

- Alan Mathison Turing was born on 23 June 1912 in a nursing home in Paddington, London. **D**
- He was a long-distance runner: he built his strength in cross-country running, was known for running to scientific meetings, and in 1951 was still training for long-distance running on the roads around Wilmslow, where he had bought his first house. **D**
- After reporting a burglary at his home in 1952 he was arrested over a relationship with another man and tried on 31 March 1952 for "gross indecency"; rather than go to prison he accepted, for a year, oestrogen treatment intended to neutralise his libido. **D**
- His biographer Andrew Hodges writes that the drug was probably stilboestrol, a synthetic oestrogen; the 2009 government statement and other sources describe the treatment as a series of injections of female hormones. **D**
- Hodges describes the injurious and humiliating effect of the hormones on his body; it is often repeated that the treatment made him grow breasts, though he is known to have mentioned this only once. **D**
- In a letter of 23 November 1952 he wrote that he had decided to have "another, and rather more co-operative go at a psychiatrist"; this was Jungian analysis with a refugee analyst, and he became very enthusiastic about it and wrote down all his dreams. **D**
- His conviction led to the removal of his security clearance, so that he could no longer work for Government Communications Headquarters as he had since the war. **D**
- After the trial he returned to a wide range of academic work, including morphogenesis, quantum theory, and relativity, at Manchester University. **D**
- The roster lists depression as a primary condition; the sources read document his prosecution, the hormone treatment, and his decision to seek Jungian analysis, but record no diagnosis of depression, so a depressive illness is a retrospective interpretation. **R**

5 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: PHQ-9: 15; GAD-7: 8; AUDIT-C: 2; Total testosterone: 112 ng/dL (low); Estradiol: 148 pg/mL (high); LH: 0.3 m[IU]/mL (low); FSH: 0.4 m[IU]/mL (low); SHBG: 88 nmol/L (high); Prolactin: 21.6 ng/mL (high); hCG (beta subunit): 1 m[IU]/mL; AFP: 2.6 ng/mL; ALT: 22 U/L; AST: 24 U/L; Total bilirubin: 0.6 mg/dL; Creatinine: 0.96 mg/dL; eGFR: 102 mL/min/1.73 m²; TSH: 1.9 mIU/L; Hemoglobin: 13 g/dL (low); 25-hydroxyvitamin D: 22 ng/mL (low). All results are synthetic.

BP 122/76 mmHg; pulse 64 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 71.4 kg; BMI 22.5 kg/m². All vital signs are synthetic.

## Current medications

- Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily **S**

## Plan so far

- Consent first: every examination, test, and treatment is explained and offered, and he may decline any of it; intimate examinations only with his agreement at each step and with a chaperone offered. The estrogen he was given as a condition of avoiding prison was not freely consented treatment, and no further doses will be given. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); APA Guidelines for Psychological Practice With Sexual Minority Persons (2021) **S**
- Gynecomastia workup: breast and testicular examination; testosterone, estradiol, LH, FSH, prolactin, SHBG, hCG, AFP, liver, kidney, and thyroid tests today; scrotal ultrasound; breast ultrasound only if the examination becomes equivocal. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018) **S**
- Watchful waiting for the gynecomastia after the estrogen stops; testosterone, estradiol, LH, and FSH every six to eight weeks until normal; no testosterone therapy while the axis is recovering; a surgical opinion if gynecomastia persists about twelve months and troubles him. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018) **S**
- Bone health: vitamin D replacement, calcium from food, continued running and strength work; bone density scan only if hypogonadism persists beyond six months or a fracture occurs. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline (2012) **S**
- Weekly psychotherapy with a gay-affirming clinic psychologist for about 16 sessions, addressing the prosecution, the coerced treatment, and minority stress; an antidepressant offered and declined for now, to be reconsidered if the PHQ-9 has not fallen by half at about eight weeks. Guideline: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); APA Guidelines for Psychological Practice With Sexual Minority Persons (2021) **S**
- Collaborative safety plan with warning signs, coping steps, people to contact, the clinic number, and the 988 Suicide & Crisis Lifeline; suicide-risk review and PHQ-9 at every visit. Guideline: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Sexual health as routine adult care: HIV and STI testing and a PrEP discussion offered at his preventive visit, with his consent; libido and erectile function reviewed as testosterone recovers. Guideline: APA Guidelines for Psychological Practice With Sexual Minority Persons (2021); Sexually Transmitted Infections Treatment Guidelines: Men Who Have Sex with Men (2021); Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis (2023) **S**
- Affirming practice: his orientation, name, and pronouns recorded as he chooses; his records shared only with his consent; a written letter from this clinic, at his request, confirming that the estrogen he was given was not medically indicated. Guideline: APA Guidelines for Psychological Practice With Sexual Minority Persons (2021) **S**
